Cargando…

Temporal antibody responses to SARS-CoV-2 in patients of coronavirus disease 2019

Detalles Bibliográficos
Autores principales:	Huang, Min, Lu, Qing-Bin, Zhao, Han, Zhang, Yulan, Sui, Zhiwei, Fang, Liqun, Liu, Di, Sun, Xiulian, Peng, Ke, Liu, Wei, Guan, Wuxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490261/ https://www.ncbi.nlm.nih.gov/pubmed/32983570 http://dx.doi.org/10.1038/s41421-020-00209-2

Ejemplares similares

Antibody Response to the Coronavirus Disease 2019 Ad26.COV2.S Vaccine Among Maintenance Dialysis Patients
por: Ficociello, Linda H., et al.
Publicado: (2022)

Serum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patients
por: Zheng, Meijuan, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Coronavirus diseases 2019 and kidney injury: a brief review based on current evidence
por: Yang, Guang, et al.
Publicado: (2021)

Pneumothorax in 2019 novel coronavirus pneumonia needs to be recognized
por: Li, Wenya, et al.
Publicado: (2020)

Detection of serum immunoglobulin M and immunoglobulin G antibodies in 2019 novel coronavirus infected patients from different stages
por: Gao, Hui-Xia, et al.
Publicado: (2020)

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
por: Cao, Yanan, et al.
Publicado: (2020)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Famotidine and Coronavirus Disease 2019
por: Freedberg, Daniel E., et al.
Publicado: (2021)

Coronavirus disease 2019 presenting with conjunctivitis as the first symptom
por: Casalino, Giuseppe, et al.
Publicado: (2020)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021)

Asthma and prognosis of coronavirus disease 2019
por: Özdemir, Öner
Publicado: (2022)

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
por: Wang, Xi, et al.
Publicado: (2020)

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
por: Roarty, Cathal, et al.
Publicado: (2021)

The presence of SARS-CoV2 antibodies in MS patients
por: Wallach, Asya I., et al.
Publicado: (2021)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

MicroCLOTS pathophysiology in coronavirus disease 2019
por: Renzi, Samuele, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 in people living with HIV
por: Yamamoto, Shinya, et al.
Publicado: (2021)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Ghafari, Mahan, et al.
Publicado: (2021)

Prevalence of SARS-Cov-2 Antibodies in Emergency Medicine Healthcare Workers
por: Wang, Ralph C., et al.
Publicado: (2021)

Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
por: Chen, Xiangyu, et al.
Publicado: (2020)

Coronavirus disease 2019 vaccine for children in China: when to start? Mandatory or voluntary?
por: Liu, Fei, et al.
Publicado: (2021)

Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection
por: Wang, Hao, et al.
Publicado: (2021)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
por: Lu, Aili, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
por: Anichini, Gabriele, et al.
Publicado: (2021)

Etoposide for Cytokine Storm Because of Coronavirus Disease 2019
por: Delgado-López, Pedro David, et al.
Publicado: (2021)

Management Issues of Sarcoidosis in the Time of Coronavirus Disease 2019
por: Tana, Claudio, et al.
Publicado: (2021)

Surveillance of endemic human Coronaviruses in Germany, 2019/2020
por: Biere, Barbara, et al.
Publicado: (2021)

What is the Determinant of 2019 Novel Coronavirus Prognosis in Children?
por: Yurttutan, Sadik
Publicado: (2000)

Zinc and Coronavirus Disease 2019: Causal or Casual Association?
por: Khurana, Alkesh Kumar, et al.
Publicado: (2021)

Exacerbation of livedoid vasculopathy after Coronavirus disease 2019
por: Kawabe, Ryoko, et al.
Publicado: (2022)

Impact of coronavirus disease 2019 on the clinical diagnosis and treatment of breast cancer in China
por: Si, Yi-Ran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u9fstssdhingvuedbim35ilmki